How drug repurposing can advance drug discovery: challenges and opportunities

Abstract

Traditional de novo drug discovery, which typically presents an 11% approval rate from phase I trials and even higher failure rates in fields like neurodegeneration, often requires two to three billion dollars and 10–17 years per new drug. In contrast, drug repurposing can reduce risks and bring drugs to the market in 3–12 years, with an average of $300 million investment. In this article, we will outline how drug repurposing can accelerate the discovery of drugs derived from natural and synthetic products. The vast amount of chemical, biological, structural, and clinical data available in public repositories will greatly facilitate drug discovery, without the need to start a discovery campaign from scratch. In the big data era, data mining and artificial intelligence will play major roles in both drug repurposing and drug discovery. This article will provide valuable insights into how drug repurposing can support drug discovery and vice versa, emphasizing its impact in addressing unmet medical needs, achieving cost-effectiveness, and enabling faster market access. Despite legal and regulatory challenges, the cost-effectiveness, and the potential to give new life to compounds already in the pipeline make drug repurposing a crucial complement to traditional drug discovery in the era of precision medicine.